27.07.2011 • News

Pharmaceutical Product Development Q2 Profit Rises

 

Pharmaceutical Product Development reported second-quarter net income attributable to shareholders of $46.51 million or $0.41 per share, compared to $20.98 million or $0.18 per share in the prior-year period.

On average, 12 analysts polled by Thomson Reuters expected earnings of $0.38 per share for the quarter. Analysts' estimate typically excludes one-time items.

Net revenue for the quarter grew 10.2% to $407.70 million from $369.92 million in the second quarter of last year, while11 analysts estimated revenues of $370.79 million for the quarter.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Book

Innovation Management in Sustainable Chemistry

Innovation Management in Sustainable Chemistry

Comprehensive resource on sustainable chemistry, bridging the skill gap between academic science education and innovation and entrepreneurship

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.